|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FMN1 |
Gene summary for FMN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FMN1 | Gene ID | 342184 |
| Gene name | formin 1 | |
| Gene Alias | FMN | |
| Cytomap | 15q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q68DA7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 342184 | FMN1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.00e-28 | -7.39e-01 | 0.0155 |
| 342184 | FMN1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 2.06e-04 | -8.00e-01 | 0.0216 |
| 342184 | FMN1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.05e-06 | -5.91e-01 | -0.1207 |
| 342184 | FMN1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.48e-04 | -7.03e-01 | -0.2061 |
| 342184 | FMN1 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.61e-08 | -5.74e-01 | 0.096 |
| 342184 | FMN1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 8.31e-07 | -7.98e-01 | 0.0528 |
| 342184 | FMN1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.69e-07 | -5.81e-01 | 0.0338 |
| 342184 | FMN1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.59e-10 | -4.72e-01 | 0.0674 |
| 342184 | FMN1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.47e-20 | -5.95e-01 | 0.294 |
| 342184 | FMN1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.38e-37 | -8.42e-01 | 0.3859 |
| 342184 | FMN1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.26e-17 | -5.66e-01 | 0.3005 |
| 342184 | FMN1 | A015-C-203 | Human | Colorectum | FAP | 2.85e-36 | -5.20e-01 | -0.1294 |
| 342184 | FMN1 | A015-C-204 | Human | Colorectum | FAP | 4.38e-06 | -3.83e-01 | -0.0228 |
| 342184 | FMN1 | A014-C-040 | Human | Colorectum | FAP | 4.09e-04 | -4.46e-01 | -0.1184 |
| 342184 | FMN1 | A002-C-201 | Human | Colorectum | FAP | 1.36e-12 | -3.55e-01 | 0.0324 |
| 342184 | FMN1 | A002-C-203 | Human | Colorectum | FAP | 1.72e-02 | -2.43e-01 | 0.2786 |
| 342184 | FMN1 | A001-C-119 | Human | Colorectum | FAP | 5.18e-06 | -4.66e-01 | -0.1557 |
| 342184 | FMN1 | A001-C-108 | Human | Colorectum | FAP | 1.42e-18 | -3.37e-01 | -0.0272 |
| 342184 | FMN1 | A002-C-021 | Human | Colorectum | FAP | 1.32e-02 | -4.43e-02 | 0.1171 |
| 342184 | FMN1 | A002-C-205 | Human | Colorectum | FAP | 6.18e-26 | -5.79e-01 | -0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00016562 | Endometrium | AEH | metanephros development | 22/2100 | 85/18723 | 1.27e-04 | 1.74e-03 | 22 |
| GO:003004110 | Endometrium | AEH | actin filament polymerization | 39/2100 | 191/18723 | 1.47e-04 | 1.96e-03 | 39 |
| GO:003083310 | Endometrium | AEH | regulation of actin filament polymerization | 35/2100 | 172/18723 | 3.36e-04 | 3.73e-03 | 35 |
| GO:000806410 | Endometrium | AEH | regulation of actin polymerization or depolymerization | 37/2100 | 188/18723 | 4.57e-04 | 4.80e-03 | 37 |
| GO:00720736 | Endometrium | AEH | kidney epithelium development | 29/2100 | 136/18723 | 4.71e-04 | 4.91e-03 | 29 |
| GO:00308329 | Endometrium | AEH | regulation of actin filament length | 37/2100 | 189/18723 | 5.08e-04 | 5.18e-03 | 37 |
| GO:00613263 | Endometrium | AEH | renal tubule development | 22/2100 | 94/18723 | 5.89e-04 | 5.82e-03 | 22 |
| GO:19018887 | Endometrium | AEH | regulation of cell junction assembly | 39/2100 | 204/18723 | 5.94e-04 | 5.86e-03 | 39 |
| GO:00518945 | Endometrium | AEH | positive regulation of focal adhesion assembly | 10/2100 | 28/18723 | 6.01e-04 | 5.91e-03 | 10 |
| GO:00351073 | Endometrium | AEH | appendage morphogenesis | 29/2100 | 138/18723 | 6.06e-04 | 5.94e-03 | 29 |
| GO:00351083 | Endometrium | AEH | limb morphogenesis | 29/2100 | 138/18723 | 6.06e-04 | 5.94e-03 | 29 |
| GO:01501175 | Endometrium | AEH | positive regulation of cell-substrate junction organization | 11/2100 | 33/18723 | 6.35e-04 | 6.20e-03 | 11 |
| GO:00720093 | Endometrium | AEH | nephron epithelium development | 24/2100 | 109/18723 | 8.69e-04 | 8.03e-03 | 24 |
| GO:00720064 | Endometrium | AEH | nephron development | 29/2100 | 142/18723 | 9.80e-04 | 8.89e-03 | 29 |
| GO:0061333 | Endometrium | AEH | renal tubule morphogenesis | 18/2100 | 75/18723 | 1.32e-03 | 1.12e-02 | 18 |
| GO:00487366 | Endometrium | AEH | appendage development | 33/2100 | 172/18723 | 1.41e-03 | 1.18e-02 | 33 |
| GO:00601736 | Endometrium | AEH | limb development | 33/2100 | 172/18723 | 1.41e-03 | 1.18e-02 | 33 |
| GO:00018232 | Endometrium | AEH | mesonephros development | 21/2100 | 96/18723 | 1.93e-03 | 1.52e-02 | 21 |
| GO:00016573 | Endometrium | AEH | ureteric bud development | 20/2100 | 91/18723 | 2.31e-03 | 1.74e-02 | 20 |
| GO:00720804 | Endometrium | AEH | nephron tubule development | 20/2100 | 91/18723 | 2.31e-03 | 1.74e-02 | 20 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FMN1 | SNV | Missense_Mutation | c.2578A>G | p.Met860Val | p.M860V | Q68DA7 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| FMN1 | SNV | Missense_Mutation | rs200873951 | c.3700C>T | p.Arg1234Cys | p.R1234C | Q68DA7 | protein_coding | deleterious(0) | possibly_damaging(0.685) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FMN1 | SNV | Missense_Mutation | c.3587G>A | p.Arg1196Lys | p.R1196K | Q68DA7 | protein_coding | tolerated(0.09) | possibly_damaging(0.809) | TCGA-AO-A12A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| FMN1 | SNV | Missense_Mutation | novel | c.4081G>A | p.Asp1361Asn | p.D1361N | Q68DA7 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
| FMN1 | SNV | Missense_Mutation | c.2522N>A | p.Leu841His | p.L841H | Q68DA7 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.781) | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | |
| FMN1 | SNV | Missense_Mutation | c.2233G>C | p.Glu745Gln | p.E745Q | Q68DA7 | protein_coding | deleterious(0) | probably_damaging(0.922) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| FMN1 | SNV | Missense_Mutation | c.3868N>C | p.Glu1290Gln | p.E1290Q | Q68DA7 | protein_coding | tolerated(0.2) | possibly_damaging(0.466) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FMN1 | SNV | Missense_Mutation | novel | c.1679N>C | p.Arg560Pro | p.R560P | Q68DA7 | protein_coding | tolerated_low_confidence(0.06) | benign(0.076) | TCGA-OL-A5RV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
| FMN1 | deletion | Frame_Shift_Del | novel | c.2111delN | p.Pro704GlnfsTer12 | p.P704Qfs*12 | Q68DA7 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| FMN1 | deletion | Frame_Shift_Del | c.3041delN | p.Asp1014AlafsTer49 | p.D1014Afs*49 | Q68DA7 | protein_coding | TCGA-E2-A156-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |